Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(5):464–468. doi: 10.1111/j.1349-7006.2004.tb03233.x

The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT‐11: Cell proliferation activity correlates with the effect of CPT‐11

Yasuaki Nakajima 1,✉, Satoshi Miyake 2, Koji Tanaka 1, Kazuo Ogiya 1, Yutaka Toukairin 1, Kenrou Kawada 1, Tetsurou Nishikage 1, Kagami Nagai 1, Tatsuyuki Kawano 1
PMCID: PMC11158489  PMID: 15132777

Abstract

Previously, we demonstrated that CPT‐11 is an effective agent against esophageal squamous cell cancers (ESCC), and that the protein level of DNA topoisomerase I can be a predictor for sensitivity to CPT‐11 (Jpn J Cancer Res 2001; 92: 1335–41). Here, we describe our search for additional predictors of sensitivity to CPT‐11, mainly among cell cycle‐regulating proteins, because the cytotoxicity of CPT‐11 is significantly correlated with the percentage of ESCC cells in S‐phase. To this end, we selected and examined the expressions of 5 proteins involved in G1‐S transition, i.e., p53, cyclin D1, p21, p27, and pRB, in 14 ESCC cell lines by western blot analysis. Among these proteins, the expression levels of p21 and pRB showed significant differences that were associated with the IC50 values for CPT‐11 (P=0.0339 and P=0.0109, respectively). Namely, the expression of p21 or pRB independently could be a good indicator of CPT‐11 efficacy in ESCC. In addition, the cell proliferation activities examined by enzyme‐linked immunosorbent assay (ELISA) using 5‐bromo‐2′‐deoxyuridine (BrdU) showed a significant correlation with the percentage of total S‐phase cells (correlation coefficient=0.568, P=0.0324), and an inverse correlation with the IC50 values for CPT‐11 (correlation coefficient=−0.601, P=0.0213). Because, as in the case of DNA topoisomerase I, the cell proliferation activity determined using BrdU shows a close relationship with the MIB‐1 labeling index, immunohistochemical studies of p21, pRB, and MIB‐1 in resected ESCC specimens and/or biopsy samples could make it possible to predict more precisely the sensitivity of ESCC patients to CPT‐11 prior to treatment.

References

  • 1. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M. Phase II evaluation of cisplatin and 5‐fluorou‐racil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992; 22: 172–6. [PubMed] [Google Scholar]
  • 2. Ando N, Ozawa S, Kitajima M, Iizuka T. Chemotherapy and multimodality therapy in the treatment of esophageal cancer. Gan To Kagaku Ryoho 1995; 22: 869–76(in Japanese). [PubMed] [Google Scholar]
  • 3. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen DP. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316–23. [PubMed] [Google Scholar]
  • 4. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Huntingt) 2002; 16: 89–96. [PubMed] [Google Scholar]
  • 5. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270–5. [DOI] [PubMed] [Google Scholar]
  • 6. Nakajima Y, Miyake S, Nagai K, Kawano T, Iwai T. CPT‐11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein. Jpn J Cancer Res 2001; 92: 1335–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 1994; 74: 3089–96. [DOI] [PubMed] [Google Scholar]
  • 8. Kawamura T, Goseki N, Koike M, Takizawa T, Endo M. Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa: immunohistochemical analysis of Ki‐67 and p53 antigen in relation to histopathologic findings. Cancer 1996; 77: 843–9. [DOI] [PubMed] [Google Scholar]
  • 9. Nakajima Y, Nagai K, Miyake S, Ohashi K, Kawano T, Iwai T. Evaluation of an indicator for lymph node metastasis of esophageal squamous cell carcinoma invading the submucosal layer. Jpn J Cancer Res 2002; 93: 305–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M, Kitajima M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 1996; 2: 1155–61. [PubMed] [Google Scholar]
  • 11. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S, Gabbert HE. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer (Pred Oncol) 1999; 84: 86–91. [DOI] [PubMed] [Google Scholar]
  • 12. Sarbia M, Stahl M, zur Hausen A, Zimmermann K, Wang L, Fink U, Heep H, Dutkowski P, Willers R, Müller W, Seeber S, Gabbert HE. Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Cancer Res 1998; 4: 2615–23. [PubMed] [Google Scholar]
  • 13. Natsugoe S, Nakashima S, Matsumoto M, Xiangming C, Okumura H, Kijima F, Ishigami S, Takebayashi Y, Baba M, Takao S, Aikou T. Expression of p21WAF1/Cipl in the p53‐dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 1999; 5: 2445–9. [PubMed] [Google Scholar]
  • 14. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834–6. [PubMed] [Google Scholar]
  • 15. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993; 119: 441–9. [DOI] [PubMed] [Google Scholar]
  • 16. Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD, Kaelin WG Jr. Cells degrade a novel inhibitor of differentiation with E1A‐like properties upon exiting the cell cycle. Mol Cell Biol 2000; 20: 8889–902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kaye FJ, Kratzke RA, Gerster JL, Horowitz JM. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA 1990; 87: 6922–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Templeton DJ, Park SH, Lanier L, Weinberg RA. Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering. Proc Natl Acad Sci USA 1991; 88: 3033–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Adams PD, Li X, Sellers WR, Baker KB, Leng X, Harper JW, Taya Y, Kaelin WG Jr. Rerinoblastoma protein contains a c‐terminal motif that targets it for phosphorylation by cyclin‐cdk complexes. Mol Cell Biol 1999; 19: 1068–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Driscoll B, T'ang A, Hu YH, Yan CL, Fu Y, Luo Y, Wu KJ, Wen S, Shi XH, Barsky L, Weinberg K, Murphree AL, Fung YK. Discovery of a regulatory motif that controls the exposure of specific upstream cyclin‐dependent kinase sites that determine both conformation and growth suppressing activity of pRB. J Biol Chem 1999; 274: 9463–71. [DOI] [PubMed] [Google Scholar]
  • 21. Lynch DA, Clarke AM, Jackson P, Axon AT, Dixon MF, Quirke P. Comparison of labelling by bromodeoxyuridine, MIB‐1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens. J Clin Pathol 1994; 47: 122–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Onda K, Davis RL, Edwards MS. Comparison of bromodeoxyuridine uptake and MIB‐1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods. J Neurooncol 1996; 29: 129–36. [DOI] [PubMed] [Google Scholar]
  • 23. Moriki T, Moriki T, Takahashi T, Kataoka H, Hiroi M, Yamane T, Hara H. Proliferation marker MIB‐1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c‐erbB‐2 and estrogen receptor status. Pathol Int 1996; 46: 953–61. [DOI] [PubMed] [Google Scholar]
  • 24. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5‐FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Huntingt) 2003; 17: 20–2. [PubMed] [Google Scholar]
  • 25. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin‐pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89: 630–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Govindan R, Read W, Faust J, Trinkaus K, Ma MK, Baker SD, McLeod HL, Perry MC. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Huntingt) 2003; 17: 27–31. [PubMed] [Google Scholar]
  • 27. Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V, Beltrami CA. Expression of p53 and bcl‐2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the esophagus. J Clin Pathol 1996; 49: 456–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam M, Meltzer SJ. P53 gene protein overexpression predicts results of trimodality therapy in eshophageal cancer patients. Ann Thorac Surg 1999; 68: 2021–4. [DOI] [PubMed] [Google Scholar]
  • 29. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 1999; 19: 5515–21. [PubMed] [Google Scholar]
  • 30. Shimoyama S, Konishi T, Kawahara M, Aoki F, Harada N, Shimizu S, Murakami T, Kaminishi M. Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer. Hepatogastroenterology 1998; 45: 1497–504. [PubMed] [Google Scholar]
  • 31. Kuwahara M, Hirai T, Yoshida K, Yamashita Y, Hihara J, Inoue H, Toge T. p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus 1999; 12: 116–9. [DOI] [PubMed] [Google Scholar]
  • 32. Nakashima S, Natugoe S, Matsumoto M, Kijima F, Takebayashi Y, Okumura H, Shimada M, Nakano S, Baba M, Takao S, Aikou T. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in eshophageal carcinoma. Anticancer Res 2000; 20: 1933–7. [PubMed] [Google Scholar]
  • 33. Kitamura K, Saeki H, Kawaguchi H, Araki K, Ohno S, Kuwano H, Maehara Y, Sugimachi K. Immunohistochemical status of the p53 protein and Ki‐67 antigen using biopsied specimens can predict a sensitivity to neoadjvant therapy in patients with esophageal cancer. Hepatogastroenterology 2000; 47: 419–23. [PubMed] [Google Scholar]
  • 34. Fukuoka K, Nishio K, Fukumoto H, Arioka H, Kurokawa H, Ishida T, Iwamoto Y, Tomonari A, Suzuki T, Ushida J, Narita N, Saijo N. Ectopic p16(ink4) expression enhances CPT‐11‐induced apoptosis through increased delay in S‐phase progression in human non‐small‐cell‐lung‐cancer cells. Int J Cancer 2000; 86: 197–203. [DOI] [PubMed] [Google Scholar]
  • 35. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr. Enhanced chemosensitivity to CPT‐11 with proteasome inhibitor PS‐341: implications for systemic nuclear factor‐kappaB inhibition. Cancer Res 2001; 61: 3535–40. [PubMed] [Google Scholar]
  • 36. Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003; 54: 194–205. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES